studies

breast cancer - triple negative, pembrolizumab alone vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsKEYNOTE-119 (all population), 2019 0.97 [0.82; 1.15] KEYNOTE-119 (PDL1 CPS>1), 2019 0.86 [0.69; 1.07] KEYNOTE-119 (PDL1 CPS>10), 2019 0.78 [0.57; 1.06] 0.90[0.80; 1.02]KEYNOTE-119 (all population), 2019, KEYNOTE-119 (PDL1 CPS>1), 2019, KEYNOTE-119 (PDL1 CPS>10), 201930%1,221moderatenot evaluable progression or deaths (PFS)detailed resultsKEYNOTE-119 (all population), 2019 1.60 [1.33; 1.92] KEYNOTE-119 (PDL1 CPS>1), 2019 1.35 [1.08; 1.68] KEYNOTE-119 (PDL1 CPS>10), 2019 1.14 [0.82; 1.59] 1.40[1.17; 1.68]KEYNOTE-119 (all population), 2019, KEYNOTE-119 (PDL1 CPS>1), 2019, KEYNOTE-119 (PDL1 CPS>10), 2019343%1,221moderatenot evaluable DCRdetailed resultsKEYNOTE-119 (all population), 2019 0.60 [0.39; 0.94] 0.60[0.39; 0.94]KEYNOTE-119 (all population), 201910%622NAnot evaluable events or deaths (EFS)detailed resultsKEYNOTE-522, 2020 0.63 [0.43; 0.93] 0.63[0.43; 0.93]KEYNOTE-522, 202010%1,174NAnot evaluable objective responses (ORR)detailed resultsKEYNOTE-119 (all population), 2019 0.89 [0.53; 1.50] KEYNOTE-119 (PDL1 CPS>1), 2019 1.35 [0.72; 2.54] KEYNOTE-119 (PDL1 CPS>10), 2019 2.13 [0.90; 5.04] 1.25[0.79; 1.99]KEYNOTE-119 (all population), 2019, KEYNOTE-119 (PDL1 CPS>1), 2019, KEYNOTE-119 (PDL1 CPS>10), 2019335%1,221moderatenot evaluable pCR detailed resultsKEYNOTE-522, 2020 13.60 [6.77; 27.33] 13.60[6.77; 27.33]KEYNOTE-522, 202010%602NAnot evaluable AE (any grade)detailed resultsKEYNOTE-522, 2020 0.25 [0.01; 4.74] 0.25[0.01; 4.74]KEYNOTE-522, 202010%1,170NAnot evaluable AE (grade 3-4)detailed resultsKEYNOTE-522, 2020 1.35 [1.01; 1.80] 1.35[1.01; 1.80]KEYNOTE-522, 202010%1,170NAnot evaluable SAE (any grade)detailed resultsKEYNOTE-119 (all population), 2019 0.99 [0.66; 1.48] 0.99[0.66; 1.48]KEYNOTE-119 (all population), 201910%601NAnot evaluable TRAE (any grade)detailed resultsKEYNOTE-522, 2020 0.25 [0.03; 2.00] 0.25[0.03; 2.00]KEYNOTE-522, 202010%1,170NAnot evaluable TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.29 [0.19; 0.43] KEYNOTE-522, 2020 1.26 [0.96; 1.66] 0.61[0.14; 2.59]KEYNOTE-119 (all population), 2019, KEYNOTE-522, 2020297%1,771lownot evaluable TRAE leading to death (grade 5)detailed resultsKEYNOTE-119 (all population), 2019 0.94 [0.37; 2.41] KEYNOTE-522, 2020 1.50 [0.16; 14.43] 1.01[0.42; 2.40]KEYNOTE-119 (all population), 2019, KEYNOTE-522, 202020%1,771moderatenot evaluable TRAE leading to discontinuation (any grade)detailed resultsKEYNOTE-119 (all population), 2019 1.05 [0.42; 2.63] KEYNOTE-522, 2020 2.16 [1.53; 3.05] 1.72[0.89; 3.31]KEYNOTE-119 (all population), 2019, KEYNOTE-522, 2020252%1,771lownot evaluable Abdominal pain TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.94 [0.06; 15.18] 0.94[0.06; 15.18]KEYNOTE-119 (all population), 201910%601NAnot evaluable Acute kidney injury TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11] 0.47[0.02; 14.11]KEYNOTE-119 (all population), 201910%601NAnot evaluable Adrenal insufficiency TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64] KEYNOTE-522, 2020 10.08 [0.59; 173.00] 5.06[0.57; 44.81]KEYNOTE-119 (all population), 2019, KEYNOTE-522, 202020%1,771lownot evaluable Alopecia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.94 [0.02; 47.78] KEYNOTE-522, 2020 0.87 [0.36; 2.09] 0.87[0.37; 2.05]KEYNOTE-119 (all population), 2019, KEYNOTE-522, 202020%1,771lownot evaluable Anaemia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.28 [0.08; 1.01] KEYNOTE-522, 2020 1.27 [0.91; 1.77] 0.68[0.16; 2.95]KEYNOTE-119 (all population), 2019, KEYNOTE-522, 2020280%1,771lownot evaluable Asthenia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.26 [0.28; 5.69] KEYNOTE-522, 2020 1.40 [0.65; 3.02] 1.37[0.69; 2.72]KEYNOTE-119 (all population), 2019, KEYNOTE-522, 202020%1,771lownot evaluable Colitis TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11] KEYNOTE-522, 2020 3.51 [0.43; 28.62] 2.02[0.34; 12.03]KEYNOTE-119 (all population), 2019, KEYNOTE-522, 202020%1,771lownot evaluable Constipation TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11] KEYNOTE-522, 2020 0.50 [0.01; 25.13] 0.48[0.04; 6.30]KEYNOTE-119 (all population), 2019, KEYNOTE-522, 202020%1,771moderatenot evaluable Cough TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64] 1.89[0.06; 56.64]KEYNOTE-119 (all population), 201910%601NAnot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11] KEYNOTE-522, 2020 3.51 [0.43; 28.62] 2.02[0.34; 12.03]KEYNOTE-119 (all population), 2019, KEYNOTE-522, 202020%1,771lownot evaluable Diabetes TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.94 [0.06; 15.18] KEYNOTE-522, 2020 1.99 [0.09; 44.34] 1.32[0.17; 10.43]KEYNOTE-119 (all population), 2019, KEYNOTE-522, 202020%1,771moderatenot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.23 [0.05; 1.10] KEYNOTE-522, 2020 1.71 [0.63; 4.67] 0.69[0.10; 4.85]KEYNOTE-119 (all population), 2019, KEYNOTE-522, 2020278%1,771lownot evaluable Dysgeusia TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 0.50 [0.01; 25.13] 0.50[0.01; 25.13]KEYNOTE-522, 202010%1,170NAnot evaluable Dyspnoea TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64] 1.89[0.06; 56.64]KEYNOTE-119 (all population), 201910%601NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.94 [0.19; 4.72] KEYNOTE-522, 2020 2.29 [0.94; 5.58] 1.86[0.85; 4.05]KEYNOTE-119 (all population), 2019, KEYNOTE-522, 202020%1,771lownot evaluable Febrile neutropenia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.05 [0.00; 0.79] KEYNOTE-522, 2020 1.13 [0.82; 1.57] 0.31[0.01; 6.85]KEYNOTE-119 (all population), 2019, KEYNOTE-522, 2020279%1,771lownot evaluable Headache TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64] 1.89[0.06; 56.64]KEYNOTE-119 (all population), 201910%601NAnot evaluable Hepatitis TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 9.06 [0.52; 156.66] 9.06[0.52; 156.66]KEYNOTE-522, 202010%1,170NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.94 [0.02; 47.78] KEYNOTE-522, 2020 1.99 [0.09; 44.34] 1.50[0.13; 17.05]KEYNOTE-119 (all population), 2019, KEYNOTE-522, 202020%1,771lownot evaluable Hypophysitis TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 8.04 [0.46; 140.38] 8.04[0.46; 140.38]KEYNOTE-522, 202010%1,170NAnot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64] KEYNOTE-522, 2020 3.00 [0.15; 59.96] 2.45[0.26; 23.20]KEYNOTE-119 (all population), 2019, KEYNOTE-522, 202020%1,771lownot evaluable Increase AST TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.91 [0.57; 6.42] KEYNOTE-522, 2020 9.67 [1.29; 72.54] 3.49[0.75; 16.21]KEYNOTE-119 (all population), 2019, KEYNOTE-522, 2020245%1,771moderatenot evaluable Increased ALT TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.90 [0.17; 21.02] KEYNOTE-522, 2020 2.34 [1.13; 4.86] 2.30[1.14; 4.63]KEYNOTE-119 (all population), 2019, KEYNOTE-522, 202020%1,771lownot evaluable Infusion-related reactions TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 2.53 [0.86; 7.45] 2.53[0.86; 7.45]KEYNOTE-522, 202010%1,170NAnot evaluable Leucopenia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.09 [0.01; 1.71] KEYNOTE-522, 2020 0.76 [0.57; 1.03] 0.45[0.07; 2.70]KEYNOTE-119 (all population), 2019, KEYNOTE-522, 2020250%1,771lownot evaluable Maculopapular rash TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64] 1.89[0.06; 56.64]KEYNOTE-119 (all population), 201910%601NAnot evaluable Myalgia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11] 0.47[0.02; 14.11]KEYNOTE-119 (all population), 201910%601NAnot evaluable Myocarditis TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 1.99 [0.09; 44.34] 1.99[0.09; 44.34]KEYNOTE-522, 202010%1,170NAnot evaluable Myositis TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 5.72 [0.29; 114.60] KEYNOTE-522, 2020 0.50 [0.01; 25.13] 2.32[0.21; 25.15]KEYNOTE-119 (all population), 2019, KEYNOTE-522, 202020%1,771moderatenot evaluable Nausea TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11] KEYNOTE-522, 2020 2.64 [1.01; 6.94] 2.33[0.92; 5.88]KEYNOTE-119 (all population), 2019, KEYNOTE-522, 202020%1,771lownot evaluable Nephritis TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.94 [0.02; 47.78] KEYNOTE-522, 2020 7.03 [0.40; 124.15] 3.49[0.34; 35.41]KEYNOTE-119 (all population), 2019, KEYNOTE-522, 202020%1,771lownot evaluable Neutropenia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.01 [0.00; 0.12] KEYNOTE-522, 2020 1.06 [0.82; 1.38] 0.11[0.00; 13.86]KEYNOTE-119 (all population), 2019, KEYNOTE-522, 2020292%1,771lownot evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.13 [0.02; 1.08] 0.13[0.02; 1.08]KEYNOTE-119 (all population), 201910%601NAnot evaluable Pancreatitis TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 4.00 [0.21; 75.85] 4.00[0.21; 75.85]KEYNOTE-522, 202010%1,170NAnot evaluable Pancytopenia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.24 [0.01; 5.23] 0.24[0.01; 5.23]KEYNOTE-119 (all population), 201910%601NAnot evaluable Peripheral neuropathy TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 1.88 [0.62; 5.72] 1.88[0.62; 5.72]KEYNOTE-522, 202010%1,170NAnot evaluable Peripheral sensory neuropathy TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.16 [0.01; 3.13] KEYNOTE-522, 2020 1.20 [0.42; 3.43] 0.72[0.13; 4.06]KEYNOTE-119 (all population), 2019, KEYNOTE-522, 2020237%1,771lownot evaluable Pneumonia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.24 [0.01; 5.23] 0.24[0.01; 5.23]KEYNOTE-119 (all population), 201910%601NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 5.72 [0.29; 114.60] KEYNOTE-522, 2020 1.50 [0.16; 14.43] 2.44[0.40; 14.85]KEYNOTE-119 (all population), 2019, KEYNOTE-522, 202020%1,771lownot evaluable Pruritus TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64] 1.89[0.06; 56.64]KEYNOTE-119 (all population), 201910%601NAnot evaluable Pyrexia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.94 [0.06; 15.18] KEYNOTE-522, 2020 4.02 [0.50; 32.22] 2.39[0.45; 12.62]KEYNOTE-119 (all population), 2019, KEYNOTE-522, 202020%1,771lownot evaluable Rash TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 3.51 [0.43; 28.62] 3.51[0.43; 28.62]KEYNOTE-522, 202010%1,170NAnot evaluable Sarcoidosis TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 0.50 [0.01; 25.13] 0.50[0.01; 25.13]KEYNOTE-522, 202010%1,170NAnot evaluable Sepsis TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.94 [0.02; 47.78] 0.94[0.02; 47.78]KEYNOTE-119 (all population), 201910%601NAnot evaluable Severe skin reaction TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.90 [0.17; 21.02] KEYNOTE-522, 2020 15.50 [2.11; 114.09] 6.06[0.78; 46.96]KEYNOTE-119 (all population), 2019, KEYNOTE-522, 2020242%1,771lownot evaluable Stomatitis TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11] KEYNOTE-522, 2020 11.10 [0.65; 189.37] 2.64[0.12; 57.65]KEYNOTE-119 (all population), 2019, KEYNOTE-522, 2020249%1,771lownot evaluable Thrombocytopenia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.94 [0.06; 15.18] 0.94[0.06; 15.18]KEYNOTE-119 (all population), 201910%601NAnot evaluable Thyroiditis TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.94 [0.02; 47.78] KEYNOTE-522, 2020 1.99 [0.09; 44.34] 1.50[0.13; 17.05]KEYNOTE-119 (all population), 2019, KEYNOTE-522, 202020%1,771lownot evaluable Urticaria TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64] 1.89[0.06; 56.64]KEYNOTE-119 (all population), 201910%601NAnot evaluable Uveitis TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 0.50 [0.01; 25.13] 0.50[0.01; 25.13]KEYNOTE-522, 202010%1,170NAnot evaluable Vomiting TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 1.51 [0.59; 3.82] 1.51[0.59; 3.82]KEYNOTE-522, 202010%1,170NAnot evaluable Weight decreased TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.47 [0.04; 5.22] 0.47[0.04; 5.22]KEYNOTE-119 (all population), 201910%601NAnot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-06-02 01:08 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 324,142,305,306,98,96,269,60,143,270,140,240 - treatments: 359,575,577,576,869

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons